{"filing":{"accession_number":"0001104659-26-099239","cik":"0001671502","ticker":"QNRX","company_name":"Quoin Pharmaceuticals, Ltd.","form":"8-K","filing_date":"2026-08-20","report_date":"2026-08-20","primary_document":"tm2623719d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1671502/000110465926099239/tm2623719d1_8k.htm"},"events":[{"id":28881,"run_id":26433,"accession_number":"0001104659-26-099239","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"Quoin Pharmaceuticals held its Annual Meeting of shareholders on August 20, 2026, with voting results on five proposals: election of seven directors, advisory approval of named executive officer compensation, approval of non-employee director compensation changes, approval of 401(k) matching contribution changes, and appointment of the independent auditor.","company_name":"Quoin Pharmaceuticals, Ltd.","ticker":"QNRX","filing_date":"2026-08-20","form":"8-K","submitted_at":null,"items":[{"id":30960,"accession_number":"0001104659-26-099239","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This section discloses the results of an Annual Meeting of shareholders held on August 20, 2026, where five proposals were voted upon: election of seven directors, advisory approval of named executive officer compensation, approval of non-employee director compensation changes, approval of 401(k) matching contribution changes, and appointment of the independent auditor. The detailed voting tallies for each proposal are presented, which is the core disclosure required under Item 5.07 for shareholder vote results.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-20T20:20:21.309482+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":28882,"run_id":26433,"accession_number":"0001104659-26-099239","anchor_item_number":"5.02","event_type":"exec_compensation","event_domain":"governance","is_material":false,"confidence":0.85,"summary":"Shareholders approved changes to the Company's 401(k) plan matching contributions for U.S.-based executive officers, representing a routine administrative adjustment to standard retirement benefits.","company_name":"Quoin Pharmaceuticals, Ltd.","ticker":"QNRX","filing_date":"2026-08-20","form":"8-K","submitted_at":null,"items":[{"id":30959,"accession_number":"0001104659-26-099239","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election","event_type":"exec_compensation","event_domain":"governance","is_material":false,"confidence":0.85,"reasoning":"The disclosure reports shareholder approval of changes to the Company's 401(k) plan matching contributions for U.S.-based executive officers. This is a compensatory arrangement modification affecting named executives, fitting the exec_compensation category. However, the materiality is low because 401(k) matching contribution changes are routine administrative adjustments to standard retirement benefits, not extraordinary compensation events or severance modifications that would significantly impact investor assessment.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-20T20:20:21.309482+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":28883,"run_id":26433,"accession_number":"0001104659-26-099239","anchor_item_number":"8.01","event_type":"governance_other","event_domain":"governance","is_material":false,"confidence":0.85,"summary":"Shareholders approved amendments to the non-employee directors' compensation program, increasing the annual base retainer cap to $250,000 and the annual option award range to $20,000–$200,000.","company_name":"Quoin Pharmaceuticals, Ltd.","ticker":"QNRX","filing_date":"2026-08-20","form":"8-K","submitted_at":null,"items":[{"id":30961,"accession_number":"0001104659-26-099239","item_number":"8.01","item_title":"Other Events.","event_type":"governance_other","event_domain":"governance","is_material":false,"confidence":0.85,"reasoning":"This disclosure reports shareholder approval of amendments to the non-employee directors' compensation program, increasing the annual base retainer cap to $250,000 and the annual option award range to $20,000–$200,000. While governance-related, this is a routine administrative amendment to director compensation terms that does not rise to the level of material executive compensation disclosure (which typically involves named executives or material plan changes affecting the company's financial position). The event is clearly governance-related but represents a standard periodic adjustment to director pay rather than a material compensation event.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-20T20:20:21.309482+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":30959,"accession_number":"0001104659-26-099239","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election","event_type":"exec_compensation","event_domain":"governance","is_material":false,"confidence":0.85,"reasoning":"The disclosure reports shareholder approval of changes to the Company's 401(k) plan matching contributions for U.S.-based executive officers. This is a compensatory arrangement modification affecting named executives, fitting the exec_compensation category. However, the materiality is low because 401(k) matching contribution changes are routine administrative adjustments to standard retirement benefits, not extraordinary compensation events or severance modifications that would significantly impact investor assessment.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-20T20:20:21.309482+00:00","company_name":"Quoin Pharmaceuticals, Ltd.","ticker":"QNRX","filing_date":"2026-08-20"},{"id":30960,"accession_number":"0001104659-26-099239","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This section discloses the results of an Annual Meeting of shareholders held on August 20, 2026, where five proposals were voted upon: election of seven directors, advisory approval of named executive officer compensation, approval of non-employee director compensation changes, approval of 401(k) matching contribution changes, and appointment of the independent auditor. The detailed voting tallies for each proposal are presented, which is the core disclosure required under Item 5.07 for shareholder vote results.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-20T20:20:21.309482+00:00","company_name":"Quoin Pharmaceuticals, Ltd.","ticker":"QNRX","filing_date":"2026-08-20"},{"id":30961,"accession_number":"0001104659-26-099239","item_number":"8.01","item_title":"Other Events.","event_type":"governance_other","event_domain":"governance","is_material":false,"confidence":0.85,"reasoning":"This disclosure reports shareholder approval of amendments to the non-employee directors' compensation program, increasing the annual base retainer cap to $250,000 and the annual option award range to $20,000–$200,000. While governance-related, this is a routine administrative amendment to director compensation terms that does not rise to the level of material executive compensation disclosure (which typically involves named executives or material plan changes affecting the company's financial position). The event is clearly governance-related but represents a standard periodic adjustment to director pay rather than a material compensation event.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-20T20:20:21.309482+00:00","company_name":"Quoin Pharmaceuticals, Ltd.","ticker":"QNRX","filing_date":"2026-08-20"}]}